0

Close
 
Upcoming Allied Market Research
2023
Over-the-counter Pain Medication Market

Over-the-Counter Pain Medication Market

by Drug Type (Acetaminophen, Nonsteroidal Anti-inflammatory Drug), by Route of Administration (Oral, Topical, Parenteral) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce, Home Care): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A12307
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Over-the-counter Pain Medication Market

Request Now !

Over-the-counter (OTC) medicines are drugs that are sold without the need for a prescription by registered pharmacists. People commonly reach for OTC pain medications to treat even the slightest physical pain, whether at work or home. OTC pain medications are available in brand and generic formulations as tablets, capsules, creams, ointments, sprays, and patches. Paracetamol is the most commonly used OTC analgesic and it does not have any anti-inflammatory effects. Paracetamol prevents prostaglandin synthesis in the central nervous system (CNS). Acetaminophen has been proposed as the first line of treatment for acute lower back pain.

COVID-19 Impact Analysis

COVID-19 is a life-threatening disease that spread all around the world. World Health Organization (WHO) declared emergency guidelines to control its spread. Governments enforced lockdown in the first half of 2020. During this period, the requirement for over-the-counter drugs showed a significant rise. COVID-19 has shown an adverse effect on patients with chronic diseases. Also, during the COVID-19 outbreak, 6 OTC drugs were approved by the Food and Drug Administration (FDA) to treat mild symptoms. People are taking the medications that work for cold or flu or fever from pharmacies. Hence, the COVID-19 pandemic has positively driven the over-the-counter pain medication market.

Top Impacting Factors

  • Over-the-counter pain medication market is expected to grow during the forecast period, as the pain suffering population is increasing in various regions and these medications are easily available in various forms such as topical, spray, lotions, and ointments to relieve pain.
  • In addition, many players are coming up with different combinations and packing styles to make the product easy to use, particularly in spray bottles.
  • Generic product makers pose as obstacle for the branded players due to price range competitions.
  • Growth in prevalence of headache, fever, muscle aches, and inflammation boosts the OTC pain medication market growth.
  • Rise in knowledge about drugs among consumers and the economical price of over-the-counter drugs are some other key factors driving the over-the-counter pain medication market.
  • However, surge in awareness among users of the adverse effects of misuse of over-the-counter pain medication hinders the growth of the market to some extent.
  • Increase in the geriatric population and prevalence of chronic pain-related disorders among the elderly population have boosted sales of OTC pain medications.

Market Trends

New Product Launches to Flourish the Market

  • In 2018, Pfizer and GSK collaborated to conduct their broad product line clinical trials under the research and developmental stage.
  • In April 2019, Granules India proclaimed that it received U.S. FDA approval for extended-release of acetaminophen tablets to be used for temporary pain relief.
  • In June 2019, BioPlus Specialty Pharmacy entered into a partnership to offer pain relievers in non-opioid pain treatment to relieve post-shingles pain, which is a type of neuropathic pain.

Surge in Usage of Acetaminophen drugs

As more people are getting involved in sports activity, more people are suffering from various pains. Key players are focusing to develop more improved product, so the pain relief time and the dose can be decreased. Various research innovations are going on to advance the product and create unique forms of products so that the patients can easily be cured of the pain. Acetaminophen is among the best purchased OTC pain medications and this drug class that holds a 45% share in the revenues of the OTC market. As acetaminophen is believed as a safer pain medication than other pain relievers, its need will continue to remain high in the market in the coming years.

Key Benefits of the Report

  • This study presents the analytical depiction of the over-the-counter pain medication along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the over-the-counter pain medication market share.
  • The current market is quantitatively analyzed to highlight the over-the-counter pain medication market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
  • The report provides a detailed analysis of the over-the-counter pain medication market based on competitive intensity and how the competition is expected to take shape in coming years.

Questions Answered in the Over-The-Counter Pain Medication Report

  • Which are the leading players active in the over-the-counter pain medication market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "over-the-counter pain medication "?
  • What is "over-the-counter pain medication" market prediction in the future?
  • Who are the leading global players in the "over-the-counter pain medication" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "over-the-counter pain medication" market report?

 Over-the-Counter Pain Medication Market Report Highlights

Aspects Details
By Drug Type
  • Acetaminophen
  • Nonsteroidal Anti-inflammatory Drug
By Route of Administration
  • Oral
  • Topical
  • Parenteral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce
  • Home Care
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players GlaxoSmithKline PLC, Pfizer, Novartis, PGT Healthcare, Sanofi, Sun Pharmaceutical Industries Ltd, Johnson and Johnson, Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, Bayer AG
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: OVER-THE-COUNTER PAIN MEDICATION MARKET, BY DRUG TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Type

    • 4.2. Acetaminophen

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Nonsteroidal Anti-inflammatory Drug

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: OVER-THE-COUNTER PAIN MEDICATION MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Topical

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Parenteral

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: OVER-THE-COUNTER PAIN MEDICATION MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail Pharmacies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. E-commerce

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Home Care

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: OVER-THE-COUNTER PAIN MEDICATION MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Drug Type

      • 7.2.3. Market Size and Forecast, By Route Of Administration

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Over-the-counter Pain Medication Market

        • 7.2.6.1. Market Size and Forecast, By Drug Type
        • 7.2.6.2. Market Size and Forecast, By Route Of Administration
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Over-the-counter Pain Medication Market

        • 7.2.7.1. Market Size and Forecast, By Drug Type
        • 7.2.7.2. Market Size and Forecast, By Route Of Administration
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Over-the-counter Pain Medication Market

        • 7.2.8.1. Market Size and Forecast, By Drug Type
        • 7.2.8.2. Market Size and Forecast, By Route Of Administration
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Drug Type

      • 7.3.3. Market Size and Forecast, By Route Of Administration

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Over-the-counter Pain Medication Market

        • 7.3.6.1. Market Size and Forecast, By Drug Type
        • 7.3.6.2. Market Size and Forecast, By Route Of Administration
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Over-the-counter Pain Medication Market

        • 7.3.7.1. Market Size and Forecast, By Drug Type
        • 7.3.7.2. Market Size and Forecast, By Route Of Administration
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Over-the-counter Pain Medication Market

        • 7.3.8.1. Market Size and Forecast, By Drug Type
        • 7.3.8.2. Market Size and Forecast, By Route Of Administration
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Over-the-counter Pain Medication Market

        • 7.3.9.1. Market Size and Forecast, By Drug Type
        • 7.3.9.2. Market Size and Forecast, By Route Of Administration
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Over-the-counter Pain Medication Market

        • 7.3.10.1. Market Size and Forecast, By Drug Type
        • 7.3.10.2. Market Size and Forecast, By Route Of Administration
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Over-the-counter Pain Medication Market

        • 7.3.11.1. Market Size and Forecast, By Drug Type
        • 7.3.11.2. Market Size and Forecast, By Route Of Administration
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Over-the-counter Pain Medication Market

        • 7.3.12.1. Market Size and Forecast, By Drug Type
        • 7.3.12.2. Market Size and Forecast, By Route Of Administration
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Drug Type

      • 7.4.3. Market Size and Forecast, By Route Of Administration

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Over-the-counter Pain Medication Market

        • 7.4.6.1. Market Size and Forecast, By Drug Type
        • 7.4.6.2. Market Size and Forecast, By Route Of Administration
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Over-the-counter Pain Medication Market

        • 7.4.7.1. Market Size and Forecast, By Drug Type
        • 7.4.7.2. Market Size and Forecast, By Route Of Administration
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Over-the-counter Pain Medication Market

        • 7.4.8.1. Market Size and Forecast, By Drug Type
        • 7.4.8.2. Market Size and Forecast, By Route Of Administration
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Over-the-counter Pain Medication Market

        • 7.4.9.1. Market Size and Forecast, By Drug Type
        • 7.4.9.2. Market Size and Forecast, By Route Of Administration
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Over-the-counter Pain Medication Market

        • 7.4.10.1. Market Size and Forecast, By Drug Type
        • 7.4.10.2. Market Size and Forecast, By Route Of Administration
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Over-the-counter Pain Medication Market

        • 7.4.11.1. Market Size and Forecast, By Drug Type
        • 7.4.11.2. Market Size and Forecast, By Route Of Administration
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Over-the-counter Pain Medication Market

        • 7.4.12.1. Market Size and Forecast, By Drug Type
        • 7.4.12.2. Market Size and Forecast, By Route Of Administration
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Over-the-counter Pain Medication Market

        • 7.4.13.1. Market Size and Forecast, By Drug Type
        • 7.4.13.2. Market Size and Forecast, By Route Of Administration
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Over-the-counter Pain Medication Market

        • 7.4.14.1. Market Size and Forecast, By Drug Type
        • 7.4.14.2. Market Size and Forecast, By Route Of Administration
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Drug Type

      • 7.5.3. Market Size and Forecast, By Route Of Administration

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Over-the-counter Pain Medication Market

        • 7.5.6.1. Market Size and Forecast, By Drug Type
        • 7.5.6.2. Market Size and Forecast, By Route Of Administration
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Over-the-counter Pain Medication Market

        • 7.5.7.1. Market Size and Forecast, By Drug Type
        • 7.5.7.2. Market Size and Forecast, By Route Of Administration
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Over-the-counter Pain Medication Market

        • 7.5.8.1. Market Size and Forecast, By Drug Type
        • 7.5.8.2. Market Size and Forecast, By Route Of Administration
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Over-the-counter Pain Medication Market

        • 7.5.9.1. Market Size and Forecast, By Drug Type
        • 7.5.9.2. Market Size and Forecast, By Route Of Administration
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Over-the-counter Pain Medication Market

        • 7.5.10.1. Market Size and Forecast, By Drug Type
        • 7.5.10.2. Market Size and Forecast, By Route Of Administration
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Over-the-counter Pain Medication Market

        • 7.5.11.1. Market Size and Forecast, By Drug Type
        • 7.5.11.2. Market Size and Forecast, By Route Of Administration
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Pfizer

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Bayer AG

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Boehringer Ingelheim

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Johnson And Johnson

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Novartis

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Sanofi

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Takeda Pharmaceutical Company Limited

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. PGT Healthcare

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. GlaxoSmithKline PLC

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Sun Pharmaceutical Industries Ltd

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR ACETAMINOPHEN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR TOPICAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR E-COMMERCE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET FOR HOME CARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA OVER-THE-COUNTER PAIN MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. U.S. OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE OVER-THE-COUNTER PAIN MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. ITALY OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. ITALY OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. ITALY OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. UK OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. UK OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. UK OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. RUSSIA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC OVER-THE-COUNTER PAIN MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. INDIA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. THAILAND OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. MALAYSIA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. INDONESIA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. LAMEA OVER-THE-COUNTER PAIN MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. BRAZIL OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. SAUDI ARABIA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 96. UAE OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 97. UAE OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 98. UAE OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. ARGENTINA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 102. REST OF LAMEA OVER-THE-COUNTER PAIN MEDICATION, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA OVER-THE-COUNTER PAIN MEDICATION, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA OVER-THE-COUNTER PAIN MEDICATION, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 105. PFIZER: KEY EXECUTIVES
  • TABLE 106. PFIZER: COMPANY SNAPSHOT
  • TABLE 107. PFIZER: OPERATING SEGMENTS
  • TABLE 108. PFIZER: PRODUCT PORTFOLIO
  • TABLE 109. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. BAYER AG: KEY EXECUTIVES
  • TABLE 111. BAYER AG: COMPANY SNAPSHOT
  • TABLE 112. BAYER AG: OPERATING SEGMENTS
  • TABLE 113. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 114. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 116. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 117. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 118. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 119. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 121. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 122. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 123. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 124. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. NOVARTIS: KEY EXECUTIVES
  • TABLE 126. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 127. NOVARTIS: OPERATING SEGMENTS
  • TABLE 128. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 129. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. SANOFI: KEY EXECUTIVES
  • TABLE 131. SANOFI: COMPANY SNAPSHOT
  • TABLE 132. SANOFI: OPERATING SEGMENTS
  • TABLE 133. SANOFI: PRODUCT PORTFOLIO
  • TABLE 134. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 136. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 137. TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 138. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 139. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. PGT HEALTHCARE: KEY EXECUTIVES
  • TABLE 141. PGT HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 142. PGT HEALTHCARE: OPERATING SEGMENTS
  • TABLE 143. PGT HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 144. PGT HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 146. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 147. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 148. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 149. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 151. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 152. SUN PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
  • TABLE 153. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 154. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET SEGMENTATION
  • FIGURE 2. GLOBAL OVER-THE-COUNTER PAIN MEDICATION MARKET
  • FIGURE 3. SEGMENTATION OVER-THE-COUNTER PAIN MEDICATION MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN OVER-THE-COUNTER PAIN MEDICATION MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALOVER-THE-COUNTER PAIN MEDICATION MARKET
  • FIGURE 11. OVER-THE-COUNTER PAIN MEDICATION MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 12. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR ACETAMINOPHEN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. OVER-THE-COUNTER PAIN MEDICATION MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 15. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR TOPICAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR PARENTERAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. OVER-THE-COUNTER PAIN MEDICATION MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 19. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR E-COMMERCE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. OVER-THE-COUNTER PAIN MEDICATION MARKET FOR HOME CARE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: OVER-THE-COUNTER PAIN MEDICATION MARKET
  • FIGURE 29. Top player positioning, 2022
  • FIGURE 30. PFIZER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. PFIZER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. PFIZER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. BOEHRINGER INGELHEIM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. NOVARTIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. NOVARTIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. NOVARTIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. SANOFI: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. SANOFI: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. PGT HEALTHCARE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. PGT HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. PGT HEALTHCARE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. SUN PHARMACEUTICAL INDUSTRIES LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Over-the-counter Pain Medication Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers